Drug Class: DPP-4 Inhibitor (Dipeptidyl Peptidase-4 Inhibitor) / Gliptin | Form: Oral Tablet | Prescription Status: Prescription Only (Rx) — DRAP Registered
What is Tagip 50mg Tablet? Tagip 50mg contains Sitagliptin Phosphate Monohydrate — a DPP-4 inhibitor at the dose-adjusted 50mg strength specifically indicated for patients with moderate kidney impairment where the standard 100mg dose is not appropriate. Since Sitagliptin is primarily eliminated through the kidneys, reduced kidney function causes drug accumulation at standard doses — increasing side effect risk. The 50mg strength allows patients with moderate chronic kidney disease to continue benefiting from Sitagliptin's effective and well-tolerated glucose-dependent blood sugar control while maintaining a safe drug exposure level. Like the 100mg strength, it works through the same incretin-enhancing mechanism — stimulating insulin release and suppressing glucagon only when blood sugar is actually elevated, maintaining the low hypoglycaemia risk profile that makes Sitagliptin particularly valuable in renally impaired and elderly diabetic patients.
What is Tagip 50mg Used For?
- Type 2 diabetes with moderate kidney impairment — dose-adjusted glycaemic control (گردوں کی اعتدالی کمزوری میں ذیابیطس ٹائپ 2 کا علاج)
- Combination therapy with Metformin — adjusted dose when kidney function is moderately reduced
- Combination with sulphonylurea — dose-reduced Sitagliptin for moderate renal impairment
- Combination with insulin — safe dose for patients with both diabetes and moderate kidney disease
- Type 2 diabetes management where hypoglycaemia risk minimisation is essential (بلڈ شوگر کنٹرول بغیر ہائپوگلائسیمیا کے خطرے کے)
How Does it Work? Sitagliptin selectively and reversibly inhibits DPP-4 enzyme — preventing rapid breakdown of GLP-1 and GIP incretin hormones after meals. Elevated active incretins stimulate pancreatic beta cells to release insulin and suppress glucagon secretion from alpha cells in a strictly glucose-dependent manner — only when blood sugar is actually elevated. At 50mg this DPP-4 inhibition remains clinically meaningful — providing effective postprandial glucose control and HbA1c reduction while maintaining the low hypoglycaemia risk inherent to the glucose-dependent incretin mechanism. The lower dose ensures safe Sitagliptin exposure in patients whose kidneys clear the drug more slowly than normal.
Dosage and Administration
⚠️ Monitor kidney function regularly — dose must be further reduced to 25mg if kidney function deteriorates to severe impairment. Never stop without doctor advice. Report any severe persistent abdominal pain immediately — pancreatitis risk. Can be taken with or without food at the same time each day.
| Indication | Usual Dose | Frequency | Notes |
|---|---|---|---|
| Moderate kidney impairment (GFR 30–50ml/min) | 50mg | Once daily | Standard dose adjustment for this renal stage |
| Combination with Metformin — moderate renal impairment | 50mg | Once daily | Metformin dose also requires assessment in kidney disease |
| Combination with sulphonylurea — moderate renal impairment | 50mg | Once daily | Sulphonylurea dose reduction may also be needed |
| Combination with insulin — moderate renal impairment | 50mg | Once daily | Insulin adjustment under doctor supervision |
Active Ingredients
| Ingredient | Strength |
|---|---|
| Sitagliptin Phosphate Monohydrate | 50mg (as Sitagliptin) |
Who Should NOT Take Tagip 50mg?
- Allergy to Sitagliptin or any DPP-4 inhibitor
- Type 1 diabetes mellitus — not indicated for Type 1 diabetes
- Diabetic ketoacidosis — requires urgent insulin therapy
- History of pancreatitis — Sitagliptin associated with increased pancreatitis risk
- Severe kidney failure — GFR below 30ml/min requires further dose reduction to 25mg
- End-stage renal disease requiring dialysis — use 25mg under specialist guidance only
- Pregnancy and breastfeeding — insulin preferred during pregnancy
- Children under 18 years — safety not established
Side Effects
Common: Mild upper respiratory symptoms — runny nose and sore throat (ناک بہنا اور گلے کا درد), mild headache, mild nausea, mild diarrhoea — very well tolerated at this lower dose with an even more favourable tolerability profile than the 100mg strength due to lower systemic exposure.
Serious — Stop and seek emergency help immediately: Acute pancreatitis — severe persistent upper abdominal pain radiating to back with nausea and vomiting (پیٹ میں شدید درد — فوری ہسپتال جائیں), severe allergic reaction — sudden widespread rash, swelling of face or throat, difficulty breathing (فوری ہسپتال جائیں), severe skin reactions — Stevens-Johnson syndrome with widespread blistering and peeling (فوری مدد لیں), significant disabling joint pain — arthralgia (جوڑوں کا شدید درد — ڈاکٹر کو بتائیں), worsening heart failure in patients with established cardiac disease (فوری مدد لیں), hypoglycaemia when combined with sulphonylurea or insulin (بلڈ شوگر کا گرنا — میٹھا کھائیں فوری).
Drug Interactions
| Medicine | Interaction |
|---|---|
| Sulphonylureas (Glibenclamide, Glimepiride) | Increased hypoglycaemia risk — sulphonylurea dose reduction typically required |
| Insulin | Increased hypoglycaemia risk — insulin dose adjustment under doctor supervision |
| Metformin | No clinically significant interaction — commonly and safely combined; however Metformin dose also requires review in moderate kidney impairment |
| Digoxin | Sitagliptin slightly increases Digoxin blood levels — monitor levels in patients on both |
| Cyclosporine | Increases Sitagliptin blood levels — monitor for increased side effects at 50mg dose |
| Corticosteroids (Prednisolone) | Raise blood glucose — may reduce Sitagliptin effectiveness; monitor blood sugar closely |
| Beta-blockers (Atenolol, Metoprolol) | Mask hypoglycaemia warning signs — important when Sitagliptin combined with sulphonylurea or insulin |
| Alcohol (شراب) | Unpredictable blood sugar effects — avoid excessive consumption |
Storage: Store below 25°C in a cool, dry place. Protect from moisture and direct sunlight. Keep out of reach of children (بچوں کی پہنچ سے دور رکھیں). Do not use after expiry date.
FAQs
Q: Why is Tagip prescribed at 50mg instead of the standard 100mg for some patients? Sitagliptin is primarily cleared by the kidneys — when kidney function is moderately reduced the drug accumulates at standard 100mg doses, increasing side effect risk. The 50mg dose is specifically calibrated to provide effective blood sugar control while maintaining safe drug exposure levels in patients with moderate chronic kidney disease.
Q: How will I know if my kidney function has worsened and I need a further dose reduction to 25mg? Your doctor will monitor kidney function through regular blood tests measuring creatinine and eGFR — if kidney function deteriorates below GFR 30ml/min your doctor will reduce Sitagliptin to 25mg. Never adjust your dose independently — always follow your nephrologist or diabetologist's specific instructions based on your kidney function results.
Q: Can Tagip 50mg be safely combined with Metformin in kidney impairment? Both Sitagliptin and Metformin require kidney function assessment in moderate renal impairment — Metformin is generally avoided or dose-reduced when GFR falls below 45ml/min due to lactic acidosis risk. Your diabetologist will assess which combination and doses are safe for your specific kidney function level.
Medical Disclaimer: This information is for general awareness only and does not replace medical advice. Always consult a qualified doctor or pharmacist before taking any prescription medicine.